Showing 81-90 of 159 results for "".
- Colorescience Expands Executive Teamhttps://practicaldermatology.com/news/20130531-colorescience_expands_executive_team/2459526/Colorescience appointed former SkinMedica CEO, Mary Fisher, who joins the brand in the same capacity. She will also serve on the Company's Board of Directors, which is chaired by David Hale of Hale BioPharma Ventures, LLC. Josie Juncal, Chief Commercial Officer for
- La Roche-Posay Awards Two Researchershttps://practicaldermatology.com/news/20120514-la_roche-posay_awards_two_researchers/2459803/At its seventh annual North American Foundation Research Awards, La Roche-Posay honored winners Sarina B. Elmariah, MD, PhD and Marie S. Tuttle, MD. Both researchers received a $10,000 grant to continue dermatological research and were honored at t
- IgE Identified as Key Mediator in Psoriasis and Atherosclerosis Comorbidityhttps://practicaldermatology.com/news/ige-identified-as-key-mediator-in-psoriasis-and-atherosclerosis-comorbidity/2471009/A new review points to immunoglobulin E (IgE) as a potential central player in the overlapping mechanisms of psoriasis and atherosclerosis. Researchers writing in Biomedicine and Pharmacotherapy proposed IgE-mediated mast cell (MC) activation as a significant contributor to the progressio
- Exosome Update: Evolve Skincare to Distribute Elevai Skin Care Products in Canadahttps://practicaldermatology.com/news/exosome-update-evolve-skincare-to-distribute-elevai-skin-care-products-in-canada/2461572/Evolve Medical Inc. is the exclusive distributor for Elevai Skincare products in Canada. The Elevai E-Series product range, a pre-and post-procedure skincare system developed with a proprietary stem cell exosome technology, will now be available to dermatologists
- New Melanoma Immunotherapy Drugs Are Saving Liveshttps://practicaldermatology.com/news/new-melanoma-immunotherapy-drugs-are-saving-lives/2461462/New research suggest that the use of new pharmacological therapies is associated with a decrease in the melanoma mortality rate in the U.S. population. In the population-based cross-sectional study of patients with cutaneous melanoma from the Surveillance, Epidemiology, and E
- EULAR: Data Show Benefit of Tremfya in PsA After Anti-TNF Failurehttps://practicaldermatology.com/news/eular-day-shown-benefit-of-tremfya-in-psa-after-anti-tnf-failure/2460834/New efficacy and safety data presented at the EULAR E-Congress suggest that first-in-class Tremfy (guselkumab) benefits adult patients with active PsA who had inadequate response or intolerance to TNF inhibitors. Trem
- Estée Lauder Companies and Atropos Therapeutics Partner to Discover Botanical Senomodulatorshttps://practicaldermatology.com/news/estee-lauder-companies-and-atropos-therapeutics-partner-to-discover-senomodulators/2460500/The Estée Lauder Companies and Atropos Therapeutics are joining forces to discover botanical senomodulators or senescence-modulating chemicals. Atropos Therapeutics Inc. has a proprietary platform to identify and develop senescence-modu
- Arcutis’ Roflumilast Cream Could Be “Game Changer” for Plaque Psoriasishttps://practicaldermatology.com/news/arcutis-roflumilast-cream-could-be-game-changer-for-plaque-psoriasis/2460467/Arcutis Biotherapeutics, Inc.’s Roflumilast cream (ARQ-151) produced significant improvements in patients with plaque psoriasis in as early as two weeks, according to a results from a phase 2b trial published in The New E
- Novel Epigenetic Mechanism May Cause Drug Resistance in Melanomahttps://practicaldermatology.com/news/novel-epigenetic-mechanism-may-cause-drug-resistance-in-melanoma/2457634/New research sheds light on epigenetic reason for drug resistance in melanoma, and identifies potential therapies that may prevent such resistance, according to a paper in Nature Communications. Mount Sinai researchers identified a novel e
- Sensus Appoints Rita Gable as VP of Sales, Oncologyhttps://practicaldermatology.com/news/sensus-appoints-rita-gable-as-vp-of-sales-oncology/2457783/Sensus Healthcare, Inc. has appointed Rita Gable as Vice President of Sales – Oncology. Ms. Gable, who will report to Joe Sardano, Sensus CEO, has 15 years of sales e